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Abstract
Salicylidene acylhydrazides identified as inhibitors of virulence-mediating type III secretion systems (T3SSs) potentially
target their inner membrane export apparatus. They also lead to inhibition of flagellar T3SS-mediated swimming motility in
Salmonella enterica serovar. Typhimurium. We show that INP0404 and INP0405 act by reducing the number of flagella/cell.
These molecules still inhibit motility of a Salmonella DfliH-fliI-fliJ/flhB(P28T) strain, which lacks three soluble components of
the flagellar T3S apparatus, suggesting that they are not the target of this drug family. We implemented a genetic screen to
search for the inhibitors’ molecular target(s) using motility assays in the DfliH-fliI/flhB(P28T) background. Both mutants
identified were more motile than the background strain in the absence of the drugs, although HM18 was considerably more
so. HM18 was more motile than its parent strain in the presence of both drugs while DI15 was only insensitive to INP0405.
HM18 was hypermotile due to hyperflagellation, whereas DI15 was not hyperflagellated. HM18 was also resistant to a
growth defect induced by high concentrations of the drugs. Whole-genome resequencing of HM18 indicated two
alterations within protein coding regions, including one within atpB, which encodes the inner membrane a-subunit of the
FOF1-ATP synthase. Reverse genetics indicated that the alteration in atpB was responsible for all of HM18’s phenotypes.
Genome sequencing of DI15 uncovered a single A562P mutation within a gene encoding the flagellar inner membrane
protein FlhA, the direct role of which in mediating drug insensitivity could not be confirmed. We discuss the implications of
these findings in terms of T3SS export apparatus function and drug target identification.
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Introduction
To battle the increasing antibiotic resistance of pathogenic
bacteria, it is crucial to develop new antimicrobial agents.
Strategies relying on existing targets and drugs, which are often
derivatives of compounds that microorganisms use to combat each
other and which directly affect bacterial viability, all face the same
problem. Resistance to the drug(s) has often already emerged in
the wild and quickly spreads under the huge selective pressure [1].
Structurally novel drugs, that specifically target virulence proper-
ties without killing bacteria and are hence unlikely to have been
previously used in nature, might decrease the chance of bacterial
resistance emerging as quickly [2]. Such compounds might also
have the advantage of sparing commensals, further reducing the
likelihood of resistance emergence and also decreasing the risk of
side effects associated with depleting the normal flora. However, a
potential disadvantage of pathogenic mechanisms as therapeutic
targets is that many are microbe-specific, necessitating more rapid
and costly pathogen identification than is available in clinical
practice at present.
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Type III secretion systems (T3SSs) are encoded by approxi-
mately 25 genes, which share homology with those encoding
bacterial flagellar basal bodies [3]. Upon direct physical contact
with host cells, T3SSs are induced to secrete and translocate
protein effectors of virulence, from the bacterial cytoplasm into the
host cell cytoplasm. They are prime target candidates for
‘‘antivirulence’’ compounds because they are so broadly distrib-
uted across Gram-negative bacterial pathogens of plants, animals
and humans, where they are often essential to virulence. However,
they are also found in a number of commensals albeit often with
unknown functions [4]. In recent years, whole-cell based high-
throughput screens have been performed to identify inhibitors of
T3SSs [5,6,7,8,9,10]. These screens have identified several classes
of synthetic compounds (salicylidene acylhydrazides, salicylanil-
ides, sulfonylaminobenzanilides, benzimidazoles and a thiazolidi-
none) and three natural products (glycolipid caminosides,
guadinomines and the linear polyketide antibiotic aurodox at
concentrations not affecting bacterial viability) as active for
inhibition of T3SSs in a range of Gram negative bacterial
pathogens, including Yersinia, Chlamydia, and Salmonella
[5,6,7,9,10,11,12,13,14,15,16,17,18,19,20,21].
Some salicylanilides and sulfonylaminobenzanilides likely in-
hibit T3SS gene transcription in EPEC [5] or Yersinia and seem
very species-specific [6,11]. A few benzimidazoles have been
shown to inhibit transcription of multiple adaptational response
family transcription factors (including LcrF of Yersinia and ExsA of
Pseudomonas) and may therefore have a broader range [9,10,18]. A
2-imino-5-arylidene thiazolidinone compound inhibited virulence-
associated T3SSs, but not flagellar biogenesis ones, and also
affected type II secretion systems. This suggests that its target is an
outer membrane component conserved between these two types of
secretion system but not found in flagellar biogenesis ones [7]. The
other T3SS inhibitors, including all identified natural products
[12,13,19,21] have unknown targets [8,19,20].
The salicylidene acylhydrazides were found to inhibit expression
and secretion of T3SS-related proteins and to affect host cell
infection by Yersinia, Chlamydia, and Salmonella [14,15,16,17,22,23].
These T3SS inhibitors were also found to reduce the motility of
Yersinia and Salmonella [11,14] and to decrease flagellin expression
and surface localization in Salmonella [14]. Taken together, these
findings indicate that the inhibitors act on a conserved target, since
they interfere with both the virulence T3SSs and the genetically,
structurally and morphologically related bacterial flagellar export
systems that mediate motility. We showed that these compounds
have a detrimental effect on T3SS needle assembly, as demon-
strated by increased numbers of T3SSs with shorter or without
needles [24]. Therefore, the compounds generate a phenocopy of
T3SS export apparatus mutants, but with incomplete penetrance.
Given the known assembly checkpoints for T3SSs and flagella
[25], this would be sufficient to almost completely block the later
secretion of effector proteins.
Further development of any of these prototype T3SS inhibitors
into novel drugs requires that their precise target(s) are identified
to allow directed small molecule improvement. Efforts have so far
focused on the initially described salicylidene acylhydrazides.
These compounds were shown to alter T3SS gene expression in E.
coli O157 [26] and their effect on the Chlamydia trachomatis and
Salmonella SPI1 T3SS can be reversed by iron [27,28], although
regulation of iron metabolism genes is unaffected by inhibitor
addition in E. coli. Recently, an affinity chromatography approach
Table 1. List of strains and plasmids used in this work.
Strain Description Reference
SJW1103 Salmonella wild-type [43]
MMHI001 DfliH-fliI [66]
MMHI0117 DfliH-fliI, flhB(P28T)
*; also known as DfliH-fliI, flhB* [40]
MMHIJ0117 DfliH-fliI-fliJ, flhB(P28T)
* [42]
DI15 Spontaneous drug insensitive and mildly hypermotile mutant This work
isolated from DfliH-fliI, flhB(P28T)
*
HM18 Spontaneous hypermotile mutant isolated from DfliH-fliI, flhB(P28T)
* This work
DfliH-fliI, flhB(P28T)
*, DatpB Deletion of the atpB gene in strain MMHI0117 This work
DfliH-fliI, flhB(P28T)
*, DfadB Deletion of the fadB gene in strain MMHI0117 This work
DfliH-fliI, flhB(P28T)
*, atpB Replacement of chromosomal atpB gene by the wild-type atpB gene This work
DfliH-fliI, flhB(P28T)
*, atpBmut Replacement of chromosomal atpB gene by the allele This work
of the atpB gene found in HM18
Plasmids Description Reference
pCP20 FLP encoding plasmid [67]
pKD4 Template plasmid for gene disruption method [49]
pUC19 High copy cloning plasmid [68]
pWSK29 Low copy cloning plasmid, with T7 promoter removed [69]
pIMA301 pUC19-atpB This work
pIMA302 pWK29-atpB This work
pIMA303 pWK29-atpB mut This work
pMM108 pUC19 His-FLAG-flhA [58]
pIMA306 pUC19 His-FLAG-flhAA562P This work
doi:10.1371/journal.pone.0052179.t001
Genetic Screen for Targets of INP0404 and INP0405
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e52179
allowed identification of three E. coli proteins that interact directly
with salicylidene acylhydrazides compounds: WrbA, an inner
membrane NADPH-dependent FMN reductase which is a
peripheral component of the electron transport chain; Tpx, a
cytoplasmic/periplasmic thiol peroxidase involved in response to
oxidative stress and FolX, an dihydroneopterin-tri-P-epimerase,
the biological role of which is unclear [29]. By transcriptomic
analysis, deletion of these genes was shown to affect flagellar and
virulence T3SS gene regulation, suggesting the drugs work by
indirect and synergistic effects on T3SS regulation.
We took a different approach, seeking to establish a system to
allow easy genetic screening for mutants resistant to the action(s) of
salicylidene acylhydrazides on T3SS function. We used the
flagellar biogenesis system in Salmonella because it is the best-
characterized T3SS genetically, functionally and structurally
(reviewed in [25]) and because motility induced by assembled
flagella leads to an economical and convenient visual screening
method.
For flagellum assembly, component proteins are transported to
the distal end of the growing structure by the flagellar type III
protein export apparatus. This consists of three soluble proteins
FliI, FliH, FliJ, and six inner membrane proteins, including FlhA
and FlhB (reviewed in [30]). FliI is an ATPase forming a
cytoplasmic complex with FliH and FliJ [31,32,33]. The six
integral membrane proteins are postulated to form the export gate
complex [34]. FliH-FliI-FliJ binds to export substrates and
chaperone-substrate complexes [35,36] and delivers them to the
docking platform of the export gate made of the C-terminal
cytoplasmic domains of FlhA and FlhB [37,38]. ATP hydrolysis by
FliI is proposed to release of the FliH-FliI-FliJ complex from the
gate [39]. The export apparatus utilises the proton-motive force
(PMF) across the cytoplasmic membrane as an energy source for
unfolding and export of substrates [40,41]. The membrane voltage
component of the PMF is sufficient to support export in the wild-
type export apparatus. However, the export gate complex
intrinsically acts as a proton-protein antiporter that uses the two
components of the PMF, the voltage and chemical potential
gradients, for different steps of the export [41,42].
We herein report the set-up of the screen and the findings that
resulted from it.
Methods
Bacterial strains
A Salmonella enterica sv. Typhimurium strain, SJW1103 [43], was
used as well as the derivatives from it listed in Table 1. They were
stored as glycerol stocks at 280uC and propagated on Luria-
Bertani (LB) agar plates or in LB broth with agitation, both
containing the appropriate antibiotics, unless otherwise stated.
Provenance and handling of small molecule inhibitors
The compounds used here are named INP (by the company
who produces them, which was formerly called Innate Pharma-
ceuticals and is now known as Creative Antibiotics at the
University of Umea˚, Sweden) followed by 4 numbers. In this
study the main the drugs used were INP0404 (compound 20 in
[15]), INP0405 (compound 9 in [15]) and INP0406 (used as a
control, [22]). Their structures, and that of the other compounds
used in Figure 1A, were published in Figure S1 of Veenendaal et al.
(2009). The compounds were prepared according to literature
protocols [44] and shipped as weighed powder in vials, where they
can be stored in the dark at room temperature for many months.
After addition of DMSO to generate 20 mM stock solutions, the
vials were kept similarly and used within 1 month. As the drugs
were used at either 50 mM or 150 mM (see below), the final
DMSO concentration in all assays was either 32 or 96 mM.
Motility assays and genetic screening
Motility assays. Motility plates were prepared using semi-
solid medium (1% Bacto Tryptone, 0.5%NaCl, 0.35% Bacto
Agar). The medium was autoclaved and cooled, if required an
inhibitor was added at 50 mM final concentration, and then it was
rapidly poured into the plates before solidifying. Single colonies
from the selected bacteria, freshly propagated onto LB plates as
above the day before, were stabbed into the medium using sterile
toothpicks. The plates were incubated at 30uC for 6–16 hours.
Genetic screening. A single colony of DfliHI/flhB* was
inoculated into LB medium and grown for 8 hr at 30uC. Motility
plates (10 cm in diameter) containing either 0.35% or 0.40%
Bacto agar and either DMSO, INP0404 or INP0405 as outlined
above were inoculated with 50 ml of bacterial culture using a
Gilson pipette tip to gently open a central line in only the top half
Figure 1. Effect of selected INP salicylidene acylhydrazides
compounds on motility and flagella numbers in wild-type
Salmonella enterica serovar Typhimurium SWJ1103. A) Motility of
Salmonella in soft agar plates containing the compounds indicated, or
the compound solvent DMSO as a control. An experiment represen-
tative of three repeats is shown. B) Electron microscopy analysis of
flagella numbers on the surface of Salmonella exposed to INP0404,
INP0405, INP0406 or DMSO. Three independent experiments were
performed. For each sample and on each experiment 20–50 cells were
scored and average number of flagella determined. In view of the
variability of the numbers obtained from day to day, the data were
normalised to the average number of flagella counted in the sample
exposed to DMSO. These numbers were 4.1 (CI +/21.5), 9.0 (CI +/22.7)
and 5.5 (CI +/21.1) for experiments 1, 2 and 3, respectively. Lines
represent the mean number for each condition. Using Poisson
regression analysis of non-normalised data, INP0404 overall significantly
reduced the number of flagella/cell (p,0.05). For INP0405, only
experiments 2 and 3 showed significant reductions in the number of
flagella/cell (p,0.001).
doi:10.1371/journal.pone.0052179.g001
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of the agar. Plates were incubated for 2 to 3 days at 30uC and
regularly examined from day 2 for mutant emergence. Well-
defined areas at the edges of the motility front where bacteria
seemed to swim better than the majority of the inoculum were
considered to contain candidate mutants. Toothpicks were used to
collect bacteria from these areas and inoculate LB broth cultures,
which were grown at 37uC overnight. Aliquots from these cultures
were streaked onto LB agar plates and incubated at 30uC
overnight to obtain single colonies. Three single colonies of each
mutant were stabbed into motility plates containing DMSO,
INP0404 or INP0405 using toothpicks. Each 10 cm plate
accommodated 3 different candidate mutants and DfliHI/flhB*
stabbed above and below the mutants in the same plate as a
control. The plates were incubated at 30uC for 7 hr. Toothpicks
were used to collect bacteria from 1 motility halo from each
mutant which had retained the initial phenotypes observed (see
Results) and these were used to inoculate LB broth cultures.
Although mutants were initially isolated from plates containing
either INP0404 or INP0405, they were subsequently rescreened
on plates containing either drug in parallel. The re-isolation
procedure was repeated at least 3 times to ensure isolate stability
and homogeneity, before each candidate mutant was stored as a
stock culture in glycerol. The overall screen was repeated several
times with 109 Salmonella being inoculated in total.
Quantitative motility assays. The quantity of cells applied
with a toothpick from a plate colony is variable and this affects the
reproducibility of the size of motility halos. To avoid this, colonies
from the selected bacteria were cultured overnight in 5 ml LB
medium at 37uC with agitation. An initial OD600 was taken in the
next morning. Overnight cultures equivalent to 1 ml OD600 = 2.5
were pelleted by centrifugation at 2000 g for 10 min. Pellets were
resuspended in 1 ml fresh LB medium and centrifuged as before.
Finally, bacterial pellets were resuspended in 20 ml LB medium.
2 ml of each sample was stabbed into the motility plates. Both the
control and the strain to be analysed were stabbed 2 or 3 times in
alternation on the same plate using three plates per colony. The
plates were incubated at 30uC for about 11 hours. Swimming halo
radii were measured by hand.
Analysis of quantitative motility assays. ‘‘Drug insensi-
tivity’’: Averages of the radii were calculated per strain and the
ratio of drug/DMSO control for a given strain (mutant or
background) was calculated. At least 4 independent colonies were
analysed per strain and drug. ‘‘Hypermotility’’: Averages of the
swimming halo radii were calculated on DMSO containing plates
and hypermotility was assessed as the ratio of mutant/background
strain for each individual plate (to normalise for differences
between plates).
Analysis of flagellar numbers
Morphology. Bacteria were cultured overnight in 5 ml LB
medium at 37uC. Overnight cultures were diluted 50-fold in 10 ml
LB broth. Drugs were added to a final concentration 50 mM.
Control cultures were incubated with DMSO at the same
concentration. Cultures were incubated at 37uC for 3–3.5 hours
until they reached approximately OD600 = 1. Cultures equivalent
to 2 ml OD600 = 1 were pelleted by centrifugation at 2000 g for
7 minutes at 4uC. Pellets were gently resuspended in 1 ml cold
sterile-filtered PBS. Pellets were collected by centrifugation at
2000 g for 7 minutes at 4uC. Two ml of PBS were added to the
pellets, which were resuspended by flicking. 5 ml of sample was
applied directly on the glow-discharged, carbon-coated side of a
300-mesh Formvar coated copper electron microscopy grid and
left for 1 minute at 25uC. The grid was put sample-side down on
drop of double distilled sterile-filtered water for 1 minute and this
step was repeated 4 times. Excess liquid was removed from the
grid with filter paper and 5 ml of 0.25% (w/v) phosphotungstic
acid pH 7 were added for 1 minute. Finally, the grid was dried
with filter paper. Grids were observed in a FEI Tecnai12 Electron
Microscope. Approximately 50 electron microscopy images were
taken on a Tecnai12 transmission electron microscope (FEI)
operating at 120 KeV. Micrographs were recorded at a magni-
fication of 6 000 on an Eagle 4K64K CCD camera (FEI) using
the TIA software (FEI). Flagella numbers per individual cell were
counted by hand.
Statistical analysis. As the flagella number/cell was skewed
towards low numbers and often zero, we chose a Poisson
regression to test for differences between experiments and between
treatments.
Growth measurements and analysis
Growth curves. Bacteria were grown overnight in 5 ml LB
broth at 37uC. An initial OD600 was taken and then cultures were
diluted 50-fold and incubated in 10 ml LB broth. In required,
T3SS inhibitors were added to 150 mM. It was previously
established that 50 mM of the drugs does not lead to any reduction
in growth rate while a slight reduction is apparent at 100 mM ([14]
and not shown). Cultures were shaken at 160 rpm at 37uC and the
OD600 was taken every hour for 6 hours.
Growth rate determination. Simple bacterial growth
curves can be described by sigmoidal functions using three
parameters: the lag time l, the maximal growth rate mm and the
asymptote of the maximal cell density A. We have used a logistic
growth model in the modification of Zwietering et al. 1990 [45]:
h(t)~
A
1zexp
4mm
A
l{tð Þz2
 
Curve fits were performed using gnuplot 4.2. All had fit errors
below 15%. The maximal growth rates mm of three independent
experiments were averaged and standard deviations were calcu-
lated.
Genomic analysis
Genomic DNA isolation. Cells grown overnight (10 ml)
were pellet by centrifugation, resuspended in 9 ml of PBS pH 7.4
and lysed with 1 ml of 20% SDS. Proteinase K (0.05 ml 20 mg/
ml) was added and the mix incubated at 37uC until the cell
suspension cleared due to lysis. RNase was added to eliminate
RNA and the mix was incubated 10 min at 60uC. Proteins were
extracted with phenol:chloroform and chloroform:isoamyl alcohol
(24:1). DNA was precipitated with 1/10 volume 3 M sodium
acetate pH 5.2 and 2.5 volume ethanol and washed with 70%
ethanol.
Whole genome sequencing. Whole-genome resequencing
was performed using the Illumina GA2 sequencing system as
described previously [46]. We generated 13,281,746 36-nucleotide
reads from HM18; that is a total of 478,142,856 nucleotides,
representing approximately 96-fold coverage of the 4.95-megabase
genome. We generated 11,150,16136-nucleotide reads from DI15,
representing approximately 81-fold coverage. To identify single-
nucleotide variants, we aligned the Illumina sequence reads
against the S. Typhimurium strain LT2 genome using the BWA
alignment tool [47] and SAMtools [48]. Regions with less than
106 coverage or less that 95% consensus were considered
ambiguous and excluded from analysis. One region of the LT2
genome, located between open reading frames STM2694–
Genetic Screen for Targets of INP0404 and INP0405
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STM2772 and seemingly encoding a bacteriophage, was entirely
missing from our data and therefore absent from the sequenced
strain. Furthermore, any sequences present in DfliHI/flhB* that
are absent from the LT2 reference would also have been omitted
from the analysis since they would not have aligned to the
reference genome. In total, of the 4,857,432 nt in the LT2
chromosome, 203,963 nt were ambiguous, leaving 4,653,469 nt of
the LT2 genome as searchable for single nucleotide changes
(SNCs).
Chromosomal alterations of atpB and fadB
All alterations were generated using the l Red system method
[49].
Construction of atpB and fadB knockout strains. To
construct the atpB and fadB mutant strains, the wild-type atpB or
fadB genes were replaced by a kanamycin cassette in Salmonella
DfliHI/flhB* as previously described [50]. To replace the wild-type
atpB gene, a kanamycin resistance cassette was amplified using
plasmid pKD4 as template and primers atpB_KO_for and
atpB_KO_rev (Table 2) that contain 50 bp flanking regions
homologous to the atpB gene. Same procedure was followed to
replace the fadB gene using primers fadB_KO_for and fadB_-
KO_rev (Table 2). Mutants where the atpB or the fadB gene has
been replaced by the kanamycin cassette were selected on plates
with kanamycin and confirmed by sequencing.
Chromosome replacement of the atpB gene. To replace
the atpB gene by the atpB allele version found in HM18, a PCR
fragment containing the atpB mutation and a kanamycin cassette
was obtained using plasmid pKD4 as template and primers
atpI_for and atpBmutant_rev. As a control, a wild-type version
was obtained by the same procedure, using instead the primer
atpwt_rev. The PCR fragments were inserted into Salmonella
chromosome as above. All gene replacements were verified by
sequencing. To eliminate the kanamycin cassette, plasmid pCP20
was used.
Construction of atpB plasmids
To complement the atpB knockout strain with the atpB wild-type
or mutant versions, the atpB gene was amplified by PCR using the
DfliHI/flhB* strain as template and primers atpB_XbaI_F and
atpB_EcoRI_rev for the wild-type version or atpB_XbaI_MUT
and atpB_EcoRI_rev for the mutant version (Table 2). PCR
fragments were digested with XbaI and EcoRI and cloned into
plasmids pUC19 or pWSK29 digested with the same enzymes
giving rise to plasmids pIMA301 and pIMA302 for the wild-type
version (in pUC19 and pWSK29 respectively) and pIMA303 for
the mutant version in pWSK29. All plasmids were verified by
sequencing.
Construction of mutant flhA plasmid
Plasmid pIMA306 (pUC19 His-FLAG-flhAA562P) was made by
two-step PCR. The first step consisted of two PCR reactions, one
carried out with primer flhA_XbaI_F2 and reverse primer
flhA_A562P_rev containing the desired mutation and the other
with flhA_A562P_for containing the mutation and flhA_Hin-
dIII_rev primers. The two PCR fragments were used as a template
for the second PCR using primers flhA_XbaI_F2 and flhA_Hin-
dIII_rev. The PCR product was purified, digested with BsaMI and
MluI and the 820 bp fragment was recloned into pUC19 His-
FLAG-flhA digested with the same enzymes.
Protein expression level measurements and secretion
assays
Secretion assays for FliC and SipC were performed largely as
previously described [51]. Briefly, bacteria were subcultured in LB
broth, by 1:100 dilution from overnight cultures, in presence of
50 mM of drugs or the equivalent amount of DMSO, for 6 to 7 hrs
at 37uC with strong aeration. After measurement of culture optical
density at 600 nm, the bacteria were pelleted by centrifugation at
2000 g for 10 min at 4uC. The supernatant was collected and
filtered using a device with a pore size of 0.2 mm to remove any
remaining bacteria. Bacterial pellets and supernatants were
resuspended or diluted to equivalent cell densities and separated
by SDS-PAGE. All supernatant samples were analysed by Silver
stain prior to Western blotting to guard against occurrence of any
bacterial lysis. The FlhA protein expression level measurements
were performed similarly except that the bacteria were only grown
Table 2. List of primers used in this studya.
Primer Sequence
atpB_KO_for ACTGGCGCCGGCTGTAATTAACAACAAAGGGTAAAAGGCATCATGGCTTCAGAAAATGTGTAGGCTGGAGCTGCTTC
atpB_KO_rev ACAGTCTCCAGTTTGTTTCAGTTAAAACGTAGTAGTGTTGGTAAATTAATGCTCTTCGGACATATGAATATCCTCCTTAG
fadB_KO_for ATCTGGTACGACCAGATCACTTTGTGGATTCAGGAGACTGACATGCTTTATAAAGGC GTGTAGGCTGGAGCTGCTTC
fadB_KO_rev GCGAATAGCATCGACAATGACAACCTGTTCCATTGTGACTCCTTAAGCCGTTTTCAGCATATGAATATCCTCCTTAG
atpB_XbaI_F TGCTCTAGACAACAAAGGGTAAAAGGCATCATGG
atpB_EcoRI_rev CCGGAATTCATTAATGCTCTTCGGACGCCATCGAC
atpB_XbaI_MUTF TGCTCTAGACAACAAAGGGTAAAAGGCATCATTTCTTCAGAAAATATG
atpI_for TTGGTGCTGGTGGTTCAGATACTGGCGCCGGCTGTAATTAACAACAAAGGGTAAAAGG GTGTAGGCTGGAGCTGCTTC
atpBwt_rev CAGATGGTGTCCTATGTATTCCTGCGGCGTCATATTTTCTGAAGCCATGATGCCTTTTACCCTTTGTTGTTCATATGAATATCCTCCTTAG
atpBmutant_rev CAGATGGTGTCCTATGTATTCCTGCGGCGTCATATTTTCTGAAGAAATGATGCCTTTTACCCTTTGTTGTTCATATGAATATCCTCCTTAG
flhA_XbaI_F2 CTAGTCTAGAGAGAAGAATACTGATGGCTAATCTGGTCGCGATGCTG
flhA_HindIII_rev ACGCAAGCTTTTATTTTCCTCCAATGGTCGCCGTC
flhA_A562P_for GGAAACGCTGCCGGAACATGCGCCGTTAC
flhA_A562P_rev GTAACGGCGCATGTTCCGGCAGCGTTTCC
aThe areas underlined correspond to restriction enzyme sites used and the base underlined and bold is the where the SNC is located that generates flhAA562P.
doi:10.1371/journal.pone.0052179.t002
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until mid-exponential phase and that only the bacterial pellets
were retained for analysis.
Western blotting
This was performed as previously described [24] using an anti-
FlhA rabbit polyclonal antiserum [52], an anti-FliC rabbit
polyclonal antiserum [34] and an anti-SipC mouse monoclonal
antibody (AC6; [53]). Signal quantification was performed by use
of an Odyssey Imaging System (Li-Cor).
Measurement of PMF components
Measurements of intracellular pH and membrane potential
were performed as previously described [42,54] in 10 mM
potassium phosphate, 0.1 mM EDTA, and 10 mM sodium lactate
after cells had been grown into mid-exponential phase in LB.
Results
INP0404 and INP0405 decrease the number of flagella
observed per wild-type Salmonella Typhimurium cell
Negrea et al. (2007) [14] reported that, out of a selection of nine
related salicylidene acylhydrazides used at 40 mM, only INP0404
and INP0405 significantly reduced the size of the swim zone of S.
enterica serovar Typhimurium strain TT16729. We have found this
to be true also in S. enterica serovar Typhimurium strain SJW1103,
using the drugs at 50 mM (Figure 1A). In addition, they reported
that at 40 mM these reduce levels of intracellular flagellin and, at
80 mM, flagellin surface presentation. Therefore, we were unsure
what was leading to the drug-specific swimming defect observed.
Since we had previously shown that some of these drugs prevent
T3SS needle assembly, presumably by preventing needle protein
secretion, in Shigella flexneri [24], we wanted to examine their effect
on flagellar assembly in Salmonella. Figure 1B shows that both
INP0404 and INP0405 reduce the number of flagella seen on the
surface of SWJ1103 relative to control compound INP0406,
although only INP0405 -which was also the stronger motility
inhibitor in the work of Negrea et al. (2007)- did so to a statistically
significant level. These data suggest that INP0404 and INP0405
act as they do in Shigella, i.e. by partially inhibiting the functions of
both the flagellar and T3SS export apparatus. The reduced level
of intracellular flagellin observed by Negrea et al (2007) could be
explained by a well-known feedback loop that represses flagellin
expression prior to hook completion [25].
INP0404 and INP0405 inhibit the weak motility of
Salmonella lacking genes encoding components of the
cytoplasmic portion of the flagellar export apparatus
Recently, it was shown that Salmonella DfliH-fliI double null
mutant strains lacking the flagellum-associated cytoplasmic
ATPase FliI and its regulator FliH, have strongly reduced but
not abolished motility. Accordingly, these strains also make very
low numbers of flagella [40,41]. This observation demonstrated
that export of flagellar components could occur in the absence of
the ATPase, which was previously thought to be the only export
energiser, i.e. only in the presence of the membrane components
of the export apparatus. These authors also showed that the
residual export seen depended on the PMF across the cytoplasmic
membrane [40,41]. We wanted to use such strains to test whether
any T3SS target of INP0404 and INP0405 was within the
cytoplasmic or membrane components of T3SSs. Minamino &
Namba isolated extragenic suppressor mutations in either of two
flagellar inner membrane proteins, FlhA and FlhB, which
enhanced the ability of the fliH-fliI double null mutant to form
flagella. We used the most motile fliH-fliI bypass mutant, DfliHI/
flhB(P28T) -hereafter referred to as DfliHI/flhB*-, and a less motile
mutant, DfliHIJ/flhB* [40], lacking a third soluble component of
the export apparatus, FliJ [42], to test whether INP0404 and
INP0405 could inhibit PMF-driven flagellar biogenesis. As shown
in Figure 2, both drugs inhibit the motility of DfliHI/flhB*, that of
DfliHIJ/flhB* and probably that of DfliHI. This indicates that
FliH, FliI, and FliJ are unlikely to be targets of the drugs.
Genetic screen for Salmonella mutants resistant to the
motility-inhibiting effect of INP0404 and INP0405 in the
DfliHI/flhB* background
In the hope of identifying the molecular target(s) of INP0404
and INP405, we searched for mutants that were more motile than
their parent strain in the presence of the drugs. This is done by
picking colonies that emerge from the outer limit of the spreading
motility fronts and hence swim better than their parent
background (see Materials & Methods and Figure 3A). This was
not possible to implement using wild-type Salmonella, which spreads
to the edge of the plate even in the presence of the drugs during
the few days necessary for mutants to emerge (not shown).
Therefore, we decided to use DfliHI/flhB* as our background
strain because it has slower motility due to its reduced number of
flagella. As shown in Figure 3A, two types of colony morphologies
were obtained that swam better than the background strain on
drug containing plates. One was transparent and the other
opaque, the latter being slightly rarer. Upon repeated re-isolation
and phenotypic screening, as described in the Methods, it became
apparent that the transparent clones swam better than the
Figure 2. Effect of INP0404 and INP0405 on motility of weakly
motile Salmonella Typhimurium strains lacking subunits of the
cytoplasmic portion of the flagellar export apparatus. Motility
assays were performed for the indicated strains in the position
displayed on the circle above the plate photographs and using DMSO
alone or the compounds indicated on the left. An experiment
representative of two independent ones is shown. When the motility
of DfliHI/flhB* and DfliHIJ/flhB* was expressed as a ratio of their motility
in either drug relative to DMSO, the average values obtained were 0.69
and 0.73, respectively, for INP0404 and 0.65 and 0.61, respectively, for
INP0405.
doi:10.1371/journal.pone.0052179.g002
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background strain in the presence and absence of the drugs
(Figure 3B). They were hence termed hypermotile (HM) mutants.
Opaque clones swam similarly to the background strain in the
absence of the drugs but better than it in presence of the drugs and
were hence termed drug-insensitive (DI). For both types of mutant,
the mutation frequency relative to the initial bacterial cell input
was calculated as approximately 1029, when 861029 to 461028 is
considered normal for rates of spontaneous mutation in Salmonella
[55], indicating that the drugs were not themselves mutagenic.
The two independent mutants, which had the strongest and
most stable phenotype in their class, HM18 and DI15, were
retained for further characterisation by quantification of their
motility relative to the background strain in the presence of the
drugs. HM18 appeared strongly resistant to the effects of INP0404
and INP0405 (Figure 4A & B). However, DI15 was only
moderately resistant to INP0405 and not to INP0404. Measure-
ment of the size of motility halos relative to that of the background
strain in the presence of DMSO alone indicated that not only
HM18 was hypermotile, but DI15 was also, albeit to a lesser
degree (Figure 5A). Therefore, we found no mutant, which was
strictly drug insensitive.
Mutant HM18 is strongly hyperflagellated, has a growth
defect and is resistant to the growth inhibitory effect of
high INP0404 and INP0405 concentrations
We wanted to understand why the mutants we had isolated
were hypermotile. Analysis of flagella numbers/cell showed that
HM18 carried significantly more flagella than its parent strain
DfliHI/flhB*, while DI15 did not (Figure 5B).
The translucent HM18 colonies on motility plates were
suggestive of a growth defect. In addition, we had noticed that
in the absence of drugs, HM18 cells were consistently ,20%
shorter and wider than DfliHI/flhB* cells during our morpholog-
ical analysis of flagella numbers (not shown). Indeed, when its
growth rate was assessed, it was found to be 3-fold lower than that
of DfliHI/flhB* (Table 3, DMSO). However, DI15 grew normally
(not shown).
We have shown previously that most salicylidene acylhydrazides
drugs that inhibit T3SS secretion have slight growth inhibitory
effects on Shigella when used above 100 mM [24]. Interestingly
however, HM18 was insensitive to the growth-inhibitory effect of
adding 150 mM INP0404 (Table 3) or INP0405 (not shown),
unlike DfliHI/flhB*.
Whole-genome sequencing of HM18 identifies mutations
within atpB and fadB genes
To identify the mutations responsible for the phenotypes of both
mutants, genomic DNA was extracted from strains DfliHI/flhB*,
HM18 and DI15 and sequenced using Illumina’s GA2 high-
throughput sequencing technology.
Figure 3. Isolation of drug resistant mutants from DfliH-fliI/
flhB*. A) An example of the types of motility fronts obtained using the
line method as described in the Materials & Methods. 0.4% agar plates
were incubated for 3 days at 30uC. Note that leading edges of the fronts
are smooth in the DMSO plate and ragged in the drug containing
plates. In the latter, two types zones are seen at the edges, some
translucent ones (white arrow pointing upwards) and some opaque
(white arrow point downwards) ones, which are more similar to the rest
of the front. Samples from both types of edge zones were taken for
mutant isolation. B) Phenotypes of triply re-isolated mutants. Names of
strains and mutants are indicated on the circle above the plates. Those
that came from opaque (left) and translucent (right) areas of motility
fronts were often DI and HM, respectively.
doi:10.1371/journal.pone.0052179.g003
Figure 4. Quantitation of motility of HM18 and DI15 in INP0404
and INP0405 relative to DfliHI/flhB*. Quantitative motility assays
were performed for the isolated mutants in the presence of A) INP0404
and B) INP0405. The motility of each strain is expressed as a ratio of its
motility in either drug relative to DMSO. Dots represent individual
colonies. Lines represent means. For INP0404, an Kruskal-Wallis test
indicated a difference between groups (p = 0.0017) and a Dunn’s post-
test indicated that only HM18 (p,0.001) was significantly more motile
than DfliHI/flhB*. For INP0405, a Kruskal-Wallis test indicated a
difference between groups (p,0.0001) and a Dunn’s post-test indicated
that HM18 (p,0.001) and DI15 (p,0.05) were significantly more motile
than DfliHI/flhB*.
doi:10.1371/journal.pone.0052179.g004
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When the sequence of mutant HM18 was compared to the one
obtained for the DfliHI/flhB* parental strain, allowing non-
ambiguous examination of 96% of the genome including the
large plasmid (Table 4), three single-nucleotide changes (SNC)
were identified within protein coding regions, specifically in the
atpB (two adjacent SNCs) and fadB genes (1 SNC). atpB encodes
the a-subunit of the FOF1-ATPsynthase and the mutation found in
HM18 disrupts its translation start site. However, there is an in-
frame start codon downstream that could be used as a new start
site. Therefore, if translated, the mutant AtpB protein would lack
its first 5 amino acids, which would affect its targeting to the inner
membrane. In addition its concentration is very likely to be
reduced due to less efficient translation initiation caused by
distancing of the new start site from the Shine-Dalgarno sequence.
fadB encodes the c-subunit of fatty acid oxidation complex. In the
HM18 strain, the protein is missing its last 147 amino as the
mutation identified causes a premature stop codon.
The fadB mutation is not responsible for the
hypermotility of HM18
In order to investigate which mutation(s) is responsible for the
hypermotile phenotype of HM18, atpB and fadB were indepen-
dently deleted in DfliHI/flhB*. The motility of the new strains was
compared with that of the DfliHI/flhB* and HM18 strains in soft
agar plates (Figure 6A). The DatpB strain was hypermotile in
comparison with DfliHI/flhB*. However no increase in motility
was seen in the DfadB strain, indicating that alteration of fadB is not
involved in HM18’s hypermotility.
The mutation in atpB causes HM18’s hypermotility
In order to confirm the role of the mutation found in the atpB
gene, DfliHI/flhB* DatpB was transformed with either the wild-type
or the atpB allele found in HM18, hereafter termed the atpB
mutant version of the gene, cloned in the low copy plasmid
pWSK29. The motility phenotype of the different strains was
analysed in soft agar plates (Figure 6B). Transformants carrying
the atpB wild-type version behaved as the parental DfliHI/flhB*
strain while transformants carrying the atpB mutant version were
as hypermotile as DatpB. This indicates that the hypermotility
phenotype in HM18 is caused by the atpB mutation. Since DatpB is
also hypermotile, the atpB mutation found in HM18 may lead to
loss-of-function by decreasing the AtpB concentration and/or the
protein’s functionality.
Figure 5. Hypermotility and flagellar numbers for isolated
mutants. A) Quantitative motility assays of each mutant relative to
DfliHI/flhB* in the presence of DMSO. Dots represent individual colonies.
Lines represent means. Kruskal-Wallis test indicated a difference
between groups (p = 0.0001) and a Dunn’s post-test indicated that
both mutant strains were significantly more motile than DfliHI/flhB*
(p,0.001). B) Number of flagella for DfliHI/flhB*, HM15 and DI15. The
display purposes, the data from two independent experiments were
pooled. Lines represent means. Using Poisson regression analysis of
unpooled data, HM18 had an overall significantly increased number of
flagella/cell (p,0.001).
doi:10.1371/journal.pone.0052179.g005
Table 3. Growth rates of various mutants and strains under different conditionsa.
Mutant/strain DMSO INP0404 DMSO/glucosec INP0404/glucose
DfliHI/flhB* 1.064+/20.101 0.495+/20.042 1.703+/20.101 1.196+/20.112
HM18 0.373+/20.019 0.290+/20.019 1.011+/20.145 0.824+/20.073
DfliHI/flhB*b 1.137+/20.130 0.577+/20.106 NAd NA
chr atpB WT
DfliHI/flhB* 0.324+/20.036 0.261+/20.040 NA NA
chr atpB mut
aThe growth rates of the strains were measured in the presence of the indicated amount of INP0404 or an equivalent volume of the drug solvent DMSO and the data
processed as outlined in the Materials and Methods. Expressed as maximal growth rate (OD600/hr). Values given are averages of three independent experiments. Errors
are standard deviations.
bGrowth rates of DfliHI/flhB* where atpB has been replaced by atpB wild-type (chr atpB WT) or atpB carrying the mutation found in HM18 (chr atpB mut) within the
chromosome.
cWhere indicated, the strains were grown in the presence of 0.4% glucose (w/v).
dNot assessed.
doi:10.1371/journal.pone.0052179.t003
Genetic Screen for Targets of INP0404 and INP0405
PLOS ONE | www.plosone.org 8 January 2013 | Volume 8 | Issue 1 | e52179
As we had previously noticed that HM18 has a growth defect
compared to the parental strain (Table 3), growth curves were
generated for these complemented strains. However, DatpB and
DatpB carrying pWSK29 with either wild-type or mutant atpB all
showed a similarly strong defect in growth compared with the
parental strain (not shown). In addition, when the DfliHI/flhB*
DatpB was complemented with wild-type atpB cloned in a high
copy number vector, the growth defect was even greater (not
shown). Taken together, these results suggest that either an
increase or a decrease in AtpB concentration can cause a growth
defect.
Chromosomal replacement of atpB by mutant but not
wild-type atpB replicates HM18’s growth defect
As expression from the chromosome would ensure that atpB is
expressed at similar levels as in the background and HM18 strains,
we replaced the atpB gene with the mutant version in the parental
DfliHI/flhB* chromosome using the l Red system [49]. When this
method is used a ‘‘scar’’ (an insertion of few nucleotides) is left in
the chromosome, therefore a wild-type atpB version was inserted
following the same procedure as a control. When growth curves
were generated for the new strains we observed that the atpB wild-
type replacement had a similar growth rate compared with the
parental strain and the atpB mutant replacement was similar to the
HM18 mutant, including in terms of insensitivity to the inhibition
of growth induced by 150 mM INP0404 (Table 3). However, when
we analysed the motility phenotype of these new strains, we found
both to be hypermotile (Figure 6C).
We conclude that changes in atpB expression levels and/or its
coding sequence cause both hypermotility and growth defects,
although which of the two phenotypes is displayed depends on the
level at which the atpB alleles are expressed.
Glucose suppresses the growth defect induced by high
drug concentrations in DfliHI/flhB*
It is well known that defects in the atp operon of Gram negative
bacteria prevent oxidative phosphorylation. In order to survive,
bacteria then increase substrate level ATP synthesis via upregula-
tion of glycolysis [56,57]. In LB medium, as used so far, bacteria
are predominantly using amino acids as carbon and energy
sources, which are a poor source of ATP via glycolysis when
oxidative phosphorylation is blocked by mutation. To test whether
at 150 mM INP0404 is directly targeting the oxidative phosphor-
ylation pathway and so causing growth to slow in LB, we sought to
stimulate ATP production via substrate level phosphorylation
during glycolysis by adding glucose to the medium. As shown in
Table 3, addition of glucose stimulates growth of DfliHI/flhB* and
HM18. Glucose also partially suppresses the growth defect
induced by 150 mM INP0404 in DfliHI/flhB* (INP0404/DMSO
ratio is 0.47 versus INP0404+glucose/DMSO+glucose ratio of
0.70) but leaves HM18 unaffected (ratios with and without glucose
of ,0.75). This indicates that the resistance to the drug-induced
growth defect in HM18 is not due to its reduced growth rate but
related instead to the physiological pathway altered within it. Since
we have shown that in HM18 the relevant altered pathway is
oxidative phosphorylation, we conclude that the drugs may be
targeting this biochemical pathway.
Molecular characterisation of DI15
Whole genome sequencing of DI15 identified a single SNC,
when compared to that of DfliHI/flhB* within flhA of the flagellar
Table 4. Summary of results of genomic analysis performed.
Chromosomal location of single
nucleotide change (SNC)a
Present
in strain
Nature of
change
Position relative
to nearby genes
Identification of
gene affected
Likely consequence
on protein product
282402 DfliHI/flhB* CRA Intergeneic region between
pseudogene cutF and proS
(prolyl-tRNA synthetase)
None NA
1248480b HM18 TRC Intergeneic region between dinI
(DNA damage inducible protein I
and pyrC (dihydroorotase)
None NA
4080164 HM18 CRA NA atpB (F0F1 ATP
synthase subunit A)
Disruption of start codon, new
in frame ATG 12 nt down
stream, truncation of 5 amino
acids of predicted periplasmic
N-terminus of AtpB
4080165 HM18 CRA NA atpB (F0F1 ATP
synthase subunit A)
Likely not translated due to
SNC 4080164, new in frame
ATG 11 nt down stream
4189753 HM18 GRA NA fadA (3-ketoacyl-CoA
thiolase, also known
as multifunctional
fatty acid oxidation
complex subunit a)
Stop codon introduced, last
147 C-terminal amino acids
missing
2008607 DI15 CRG NA flhA (core inner
membrane component
of the flagellar export
apparatus)
Single amino acid change
introduced, A562P
aDefined by whole-genome Illumina sequencing and comparison to the Salmonella Typhimurium LT2 chromosome (RefSeq:NC_003197) and the 100-Kb plasmid pSLT
(RefSeq:NC_003277). No differences were found between the plasmid of the LT2 reference and the two test strains.
bNote that this mutation (but no other) was also found in HM16 and DI13, which are not further described here, but not in DfliHI/flhB*. We thus assume it to be
phenotypically silent.
doi:10.1371/journal.pone.0052179.t004
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inner membrane export apparatus that leads to FlhAA562P. Since
,96% of the genome of DfliHI/flhB* was searchable for SNCs and
no other was found, it is very likely to be solely responsible for the
phenotype seen in this background. However, when we tried to
complement DflhA DfliHI/flhB* with flhAA562P versus flhA, using
the pMM108 His-FLAG-FlhA complementation plasmid [58] and
inserting the flhAA562P allele to generate a second version of this
plasmid, we were unable to assess the DI phenotype because
restoration of motility with WT flhA was too poor even upon
extended incubation times (data not shown). We next examined
the effect of FlhAA562P in an otherwise wild-type background. For
this we used a previously generated DflhA strain [59]. Although
variable, complementation of this strain with flhA was more
successful. Yet, relative to flhA, the flhAA562P allele alone did not
lead to insensitivity to INP0405 or to the slight hypermotility
observed in DI15 (data not shown).
Influence of HM18 and DI15 backgrounds on T3SS
function
We wanted to understand how the mutations we had uncovered
affected not only flagellar but virulence-related T3SSs. In S.
Typhimurium, two 2 virulence T3SSs exist, SPI1 and SPI2 [14].
SP1 is required for invasion of eukaryotic host cells and SPI2 for
replication inside them, within a membrane-bound vacuole. SPI1
is expressed in LB but SPI2 expression requires growth in a
medium low in nutrients and magnesium at pH 5 [60]. As
expected, HM18 grew very poorly in MgM-MES (not shown).
Therefore, we could not establish the effect of our mutant
backgrounds on the SPI2 secretion system. However, we were able
to examine expression and secretion of FliC by the flagellar T3SS
and of SipC, by the SPI1 secretion system (Figure 7). FliC and
SipC expression and secretion are increased approximately 2-fold
in HM18, relative to either DI15 or DfliHI/flhB* in the presence of
DMSO. However, their expression is strongly reduced (2 to 7-fold)
during growth in the presence of either drug, as previously
reported [14], in all three strains examined here. Despite this, the
secretion of FliC is almost unaffected by addition of either drug in
the HM18 background, while it is also not fully reduced to DfliHI/
flhB* levels in DI15 (Figure 7, top panel). This indicates that
secretion of FliC is oblivious to drug addition in the HM18
background, while it is less sensitive to drug addition in the DI15
background. Expression of SipC is almost abolished in the
presence of either drug (Figure 7, bottom panel), as previously
reported [14], in all strains tested. However, SipC secretion is still
,2-fold higher in HM18 than in DfliHI/flhB* or DI15. Taken
together, these data indicate that the effect of the flhA mutation in
DI15 is autonomous to flagellum assembly while that of the
alteration of atpB in HM18 is not.
Figure 7. Influence of the DI15 and HM18 backgrounds on the
function of flagellar and virulence-related T3SSs. Strain DfliHI/
flhB*, DI15 and HM18 were grown to late exponential phase in the
presence of DMSO, or 50 mM INP0404 or INP0405 and normalised for
OD600. Cultures were separated into cell pellet and culture supernatant
by centrifugation, followed by SDS-PAGE and Western blotting with
anti-FliC (flagellin, top) and anti-SipC (SPI1 T3SS effector, bottom)
antibodies. A representative experiment is shown.
doi:10.1371/journal.pone.0052179.g007
Figure 6. Analysis of the role of atpB and fadB in the
hypermotility of HM18. A) Deletion of atpB but not fadB leads to
hypermotility in the DfliHI/flhB* background. DfliHI/flhB*, DfliHI/flhB*
DatpB and DfliHI/flhB* DfadB were stabbed into motility agar and
incubated at 30uC for 16–18 hr. A representative experiment is shown.
B) Extrachromosomal complementation of DatpB with wild-type but
not mutant atpB restores weak motility to DfliHI/flhB*. DfliHI/flhB* DatpB
and DfliHI/flhB* DatpB complemented with atpB wild-type (atpB WT) or
atpB carrying the mutation found in HM18 (atpB mut) on a low copy
plasmid were stabbed into motility agar along side DfliHI/flhB* and
incubated at 30uC for 16–18 hr. A representative experiment is shown.
Although DfliHI/flhB* DatpB/patpB mut appears somewhat more
opaque than the equivalently hypermotile DfliHI/flhB* DatpB, both it
and DfliHI/flhB* DatpB/patpB wt (which is not hypermotile) had similar
growth defects in liquid culture. This suggests that their growth defects
may be or appear somewhat different in motility medium. C)
Chromosomal replacement of atpB by mutant and wild type atpB in
DfliHI/flhB* both lead to hypermotility. Motility analysis for the same
two strains in comparison to HM18 and DfliHI/flhB*. The plate was
incubated at 30uC for 16–18 hr. A representative experiment is shown.
doi:10.1371/journal.pone.0052179.g006
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Discussion
It was proposed that drugs inhibiting virulence-associated
instead of ‘‘house-keeping’’ functions in bacteria would lead to
reduced resistance emergence [61]. Evidently, the frequency of
mutant emergence found here corresponds to that of spontaneous
mutation in Salmonella. Moreover, in the host, where virulence-like
T3SS are essential to survival and replication, and flagellar T3SS
are important for host colonisation by commensals and pathogens
alike, presence of T3SS inhibitors may generate a selective force
for resistance emergence. However, there should be less pressure
for general drug handling mechanisms, which are easily mobilis-
able and hence transferable, to evolve since their targets are non-
essential. In addition, resistance to virulence inhibitors should not
pre-exist in the environment, with novel target site mutations
being especially poorly mobilisable since the functions targeted are
not as conserved as those targeted by antibiotics.
Study of the development of antibiotic resistance showed that
this occurs by four main mechanisms: 1) enhanced drug export,
reduced entry or degradation, 2) up-regulation of expression of the
drug target and 3) mutation of the drug target or 4) acquisition of a
modified target [1]. When screening for resistance to antibiotics,
the first 3 classes of mutants are often identified. HM18 did not
reveal mutations in genes encoding the putative T3SS target(s) of
the drugs that our work in Shigella [24] and Salmonella (above) had
led us to expect. We discuss first why we think HM18 is an unusual
representative of a class 2 mutant. On the other hand DI15 does
carry a mutation within a flagellar export apparatus but we discuss
further below why we do not think it represents a class 3 mutant
and may therefore be a weaker representative of a class 2 mutant.
What does the study of HM18 indicate about flagellar
protein secretion and the mechanism(s) of action of the
drugs?
Hyperflagellation. Our complementation data show that
the alteration in atpB within HM18 is responsible for both the
hyperflagellation, causing an increase in motility, and for its
growth defect. Alterations of the atpB operon are known to cause
growth defects [56]. Indeed, when we deleted atpB in the wild-type
background SJW1103, we saw the same growth defect, but we did
not see an increase in motility (not shown). Therefore, how might
an alteration in atpB in the DfliHI/flhB* background cause
hyperflagellation?
Under aerobic growth conditions, as used in our work, the PMF
generated by the respiratory electron transport chain across the
cytoplasmic membrane is used by the FOF1-ATP synthase to
generate ATP. Loss-of-function in the atp operon would lead to a
decrease in intracellular ATP levels and an increase in free protons
in the periplasm, to a point where the electron transport chain
stops and NADH levels build up, blocking the remaining source of
ATP, i.e substrate-level phosphorylation via glycolysis. However,
this does not occur because bacteria have evolved compensatory
mechanisms to deal with this scenario, including upregulation of
glycolysis to provide ATP by substrate level phosphorylation and
upregulation of certain components of the electron transport chain
to allow faster re-oxidation of NADH whilst avoiding an increase
in the PMF [57].
In DfliHI/flhB*, flagellar protein export is entirely driven by the
PMF [40]. Hence, in this background, an increase in the PMF
seen in the absence of sufficient or functional FOF1-ATP synthase
may be dissipated by a proton-conducting channel within the
flagellar export apparatus. This is consistent with similarly
increased motility in a strain lacking a component of the flagellar
C-ring (which supports the function of cytoplasmic export
apparatus) and carrying a deletion of atpA [62]. This process
would stimulate export of flagellar proteins (as seen in Figure 7),
hence stimulating flagellation, and at the same time, allow re-
oxidation of NADH by the electron transport chain, facilitating
ATP synthesis by substrate-level phosphorylation in glycolysis.
Indeed, Figure 8 shows that the hypermotility seen in DfliHI/flhB*
DatpB is probably not due to an increased number of basal bodies,
as evidenced by the similar levels of FlhA detected by Western
blotting in this strain versus DfliHI/flhB* Indeed, the number of
basal bodies formed per bacterium is known to be regulated
upstream of filament completion [25]. Hence, the hypermotility of
this strain -and HM18- is most likely due to an increase in the
number of basal bodies able to polymerise a flagellum.
However, we measured the PMF components in SJW1103,
DfliHI/flhB*, SJW1103 DatpB and DfliHI/flhB* DatpB and found
no difference in the overall PMF in any of these strains (not
shown). Therefore, if the export apparatus in the flagellar T3SS
does serve to dissipate some of the increased PMF in DfliHI/flhB*
when atpB is deleted, the differences produced in the PMF
components are too small or too local to be detectable in SJW1103
under our experimental conditions DatpB [57].
Apparent resistance to drug-induced motility defect
During our experiments with atpB-modified strains, we noticed
a correlation of hypermotility with drug resistance and not with
growth defects. First, chromosomal replacements of atpB by
mutant and wild-type forms in DfliHI/flhB* are both hypermotile
and also seemingly resistant to INP0404 and INP0405 (not
shown), but only the mutant replacement leads to a growth defect.
Second, plasmid complementation of DatpB by either a wild-type
or mutated version of the gene leads to a growth defect. However,
only DfliHI/flhB* DatpB/patpB mut is hypermotile and drug
resistant, whereas DfliHI/flhB* DatpB/patpB wt is neither. There-
fore, apparent drug resistance is linked to hypermotility in these
strains. We propose that HM18 seems drug resistant because it is
hyperflagellated. Since the intracellular amount of a flagellar basal
component is unaltered (Figure 8), this is unlikely to represent a
typical class 2, ‘‘target upregulation’’, mutant. Instead, it is rather a
case of ‘‘function upregulation’’. As it secretes more flagellin
(Figure 7), HM18 probably produces more flagella than DfliHI/
flhB* in absence of any drug. Addition of either drug reduces the
number of flagella HM18 produces (not shown) and its motility,
indicating that the mutant is still sensitive to the effects of the drugs
Figure 8. Measurement of FlhA expression in DfliHI/flhB* under
different conditions. Whole cell extracts of DfliHI/flhB* carrying or
not the chromosomal deletion in atpB, grown to mid-exponential phase
in the presence of DMSO, or 50 mM INP0404 or INP0405 and normalised
for OD600, were separated by SDS-PAGE and Western blotted with an
anti-FlhA antiserum. No difference in FlhA level was observed under any
of the conditions tested.
doi:10.1371/journal.pone.0052179.g008
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on flagellation. But, the drugs do not affect HM18’s ability to
express and secrete flagellin as much as they do for DfliHI/flhB*.
In addition, motility probably does not correlate linearly with
number of flagella, of which DfliHI/flhB* has fewer to start with,
adding to appearance of drug resistance by HM18.
Resistance to drug-induced growth defect
HM18 displays a growth defect. In addition, it is less sensitive to
growth-inhibitory effect of high concentrations of the drugs than
DfliHI/flhB*. This suggests that at these concentrations at least, the
drugs are detectably influencing the oxidative phosphorylation
pathway, which is defective in HM18. As HM18 displays near
complete resistance to the drug-induced growth defect, it may be
that at 150 mM the drugs are targeting AtpB directly. Many small
molecules inhibitors of mammalian and/or bacterial ATP
synthase are known [63,64]. Alternatively, in view of the results
of Wang et al. (2011), the physical targets of the drugs in this
pathway may be elsewhere. Indeed, these authors identified two
proteins, WrbA and Tpx, which are involved in oxidative
metabolism, as directly interacting with salicylidene acylhydrazides
[29]. This suggests that a primary target of these drugs may
instead be within the electron transport chain. Their effect on the
electron transport chain may even have contributed positively to
selection of the atpB mutation in our screen. Indeed our atpB
mutation would be expected to uncouple ATP synthesis from a
membrane-functional electron transport chain due to its stimula-
tion of substrate-level phosphorylation [65] and this would be
beneficial to bacteria growing under the pressure of a drug that
inhibits the electron transport chain (Figure 9).
Link between the PMF, flagellation, motility and growth
If the drugs really were inhibitors of the electron transport
chain, they should lead to a reduction in proton concentration in
the periplasm. This would explain why they reduce flagellation in
and hence ultimately motility of HM18 in soft agar. This is also
consistent with the fact that we and others found that at 50 mM,
their inhibitory effect on T3SSs requires a pre-treatment of at least
30 min, i.e. ,1 bacterial generation time, but is rapidly reversible
[15,24]. However, at 50 mM the drugs do not detectably reduce
swimming speeds of S. Typhimurium in liquid culture (not shown),
suggesting that the proton-driven rotary flagellar motor is
unaffected by any reduction in periplasmic protons induced at
this drug concentration. Finally, bacterial growth is only affected
beyond 100–150 mM of the drugs. Overall, this indicates that
probably flagellar and virulence T3SSs are sensitive to smaller
decreases in the PMF than flagellar rotation and growth are.
The DI15 mutation probably does not identify a target of
INP0405 within the flagellar T3SS apparatus
Only one SNC was found in DI15’s genome, which leads to the
A562P mutation within FlhA, a polytopic inner membrane protein
of the flagellar export apparatus. This suggested that its weak
insensitivity to INP0405 is specific to this SNC. However, for
technical reasons, we could not test this directly via complemen-
tation of DflhA DfliHI/flhB* and when we examined the effect of
flhAA562P in a DflhA background, we found that it did not lead to
either the mild INP0405 resistance or the mild hypermotility
observed in DI15. This suggests that the flhAA562P does not
mediate resistance directly. Instead, it may do so indirectly,
perhaps via enhancement of the effect of the flhB* mutation in the
DfliHI background. Indeed, several flhA* alleles were previously
found in the DfliHI background [40]. If the drugs did lead to a
decrease in the number of protons in the periplasm, any
enhancement of flagellation by flhAA562P in DfliHI/flhB* would
lead to apparent resistance (Figure 9). Within this framework,
DI15 would be insensitive to INP0405 and not INP0404 (Figure 4)
because, of the two, INP0405 is the strongest inhibitor of motility
and flagellation (Figure 1) and therefore, probably also of the
electron transport chain. Hence INP0405 would create the
greatest flagellation and hence motility differential between DI15
and DfliHI/flhB*. This would be in agreement with the findings of
Tree et al. (2009; [26]) who identified a strain of E. coli O157,
ZAP-430, that showed no inhibition of T3SS secretion by four
different salicylidene acylhydrazides. Sequencing of its genome
and comparison against an E. coli strain that remained sensitive to
the effects of the drugs on T3SS secretion identified numerous
SNCs but none in T3SS operons, suggesting a lack of direct T3SS
targets for these drugs.
Figure 9. Comparative schematic representation of the bacterial flagellar export apparatus and FO/F1 ATPase. The bacterial
cytoplasmic membrane (CM) is shown in dark gray blocks. Peri stands for periplasmic face and Cyto for cytoplasmic face. The names components that
are functionally and/or structurally related between the two complexes (as described in the Discussion) are outlined in black and share similar colours
and/or shapes.
doi:10.1371/journal.pone.0052179.g009
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INP0404 and INP0405 may affect virulence-related T3SSs
in the same indirect manner as they affect flagellar
biogenesis
Finally, we showed that SPI1 function is upregulated in HM18
but not in DI15 and that in HM18 it is mildly resistant to drug
addition. The mildness of this effect is probably the consequence of
two facts: 1) the drugs severely decrease SPI1 gene expression [14]
and 2) in DfliHI/flhB* and its derivatives, the SPI1 secretion
system, unlike the flagellar one, still has a functional export
ATPase. When this protein complex is present, it affects how the
PMF is used in T3SS-mediated export, making its role less
apparent [40,42]. Nevertheless, these findings support the notion
that flagellar and virulence-related T3SS are similarly affected in
HM18, but not in DI15. The flhA mutation in DI15 would be
expected to be autonomous to flagellar function because it lies in a
gene encoding a flagellar component. However, that the atpB
mutation in HM18 also affects SPI function alone and in the
presence of the drugs suggests that these may be affecting virulence
T3SSs in the same manner as they do flagellar ones.
All together therefore, our findings suggest that salicylidene
acylhydrazides are not direct ‘‘virulence blockers’’. Instead, they
affect virulence indirectly via a generalised, if low level at the
concentrations initially used, disruption of basic bacterial physi-
ology. In the long-term, such virulence blocking small molecules
may be easier to identify using rational design, or high-throughput
screens on defined molecular targets rather than on whole cell
assays.
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